ST-Segment Elevation Myocardial Infarction
Conditions
Interventions
Experimental group:While receiving conventional Western medical treatment (such as aspirin clopidogrel RAAS inhibitors statins beta-blockers etc.) patients will also take Wenxin Decoction Granules.
Control group:Receive conventional Western medicine treatment while taking Wenxin Decoction placebo
Sponsors
Guang'anmen Hospital China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years old 2. Patients with acute anterior ST-segment elevation myocardial infarction (STEMI) within 10 days who received emergency percutaneous coronary intervention (PCI) within 12 hours 3. Patients with acute myocardial infarction who meet the syndrome type of qi deficiency and blood stasis 4. Patients have signed the informed consent form
Exclusion criteria
Exclusion criteria: 1. Cardiopulmonary resuscitation (CPR) lasting over 20 minutes 2. Presence of significant mechanical complications at enrollment including ventricular septal rupture papillary muscle or chordae tendineae rupture or left ventricular free wall rupture 3. Severe cardiogenic shock acute myocardial infarction (AMI) complicated by heart failure (HF) Killip class III or IV 4. Malignant arrhythmias 5. History of bleeding in the cerebrovascular gastrointestinal respiratory urinary tract or other organs within 1 month 6. Patients with diseases expected to have a life expectancy of less than 6 months 7. Severe mental disorders 8. Pregnant or lactating women 9. Patients allergic to the components of the test drug or taking other traditional Chinese medicines 10. Severe hepatic or renal insufficiency (ALT AST >3 times the upper limit of normal; BUN Cr >3 times the upper limit of normal) 11. Patients previously diagnosed with old myocardial infarction cardiomyopathy valvular heart disease pulmonary hypertension or other conditions that may cause ventricular remodeling prematurely 12. Patients currently participating in other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of ventricular remodeling with clinical significance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Left Ventricular Mass Index;Left Ventricular End-Systolic Volume;Left ventricular end-diastolic diameter;Incidence of heart failure with reduced ejection fraction (HFrEF);Left Ventricular End-Diastolic Volume Index;Left Ventricular End-Systolic Diameter;Left Ventricular End-Diastolic Volume;Levels of inflammatory factors;Left Ventricular End-Systolic Volume Index;Traditional Chinese Medicine Syndrome Score;Complications of STEMI within 28 days; Incidence of MACCE events within 3 months;Risk of all-cause mortality;Minnesota Living with Heart Failure Questionnaire (MLHFQ);NYHA classification score;Exploratory indicators: TGF-ß1, p-Smad2/3, Smad7; | — |
Countries
China
Contacts
Public ContactJun Li
Guang'anmen Hospital China Academy of Chinese Medical Sciences
Outcome results
None listed